Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

Z
Zabernigg, August F.

Department of Internal Medicine, County Hospital Kufstein
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
August F. Zabernigg
Favorite
Zafar, Syed F.

Florida Cancer Specialists & Research Institute
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Syed F. Zafar
Favorite
Zaja, Francesco

Department of Medical, Surgical and Health Sciences, University of Trieste
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Francesco Zaja
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Francesco Zaja
Favorite
Zamprogna, Giulia

Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Giulia Zamprogna
Favorite
Zatezalo, Viktor

University Hospital Merkur
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Viktor Zatezalo
Favorite
Zekanovic, Ivan

GH Zadar
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Ivan Zekanovic
Favorite
Zelenetz, Andrew

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Andrew Zelenetz
Favorite
Zent, Clive

Wilmot Cancer Institute / University of Rochester Medical Center
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Clive Zent
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Clive Zent
Favorite
Zettler, Christina

COTA, Inc.
1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States
Christina Zettler
Favorite
Zevnik, Branko

CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Branko Zevnik
Favorite
Zhai, Yifan

Ascentage Pharma Group Inc. and Ascentage Pharma (Suzhou) Co., Ltd.
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Yifan Zhai
Favorite
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Yifan Zhai
Favorite
Zhang, Can

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Can Zhang
Favorite
Zhang, Jiale

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1008 - XPO1 inhibitor Selinexor induces heme oxygenase-1 mediated p53-dependent ferroptosis in chronic lymphocytic leukemia
Jiale Zhang
Favorite
1047 - Prognosis Analysis and Validation of Fatty Acid Metabolism-Related Signature in Chronic lymphocytic leukemia
Jiale Zhang
Favorite
Zhang, Jiewen

TechData Service Company, LLC, PA, USA
2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor
Jiewen Zhang
Favorite
Zhang, Jun

BeiGene USA, Inc.
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Jun Zhang
Favorite
Zhang, Kai
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Kai Zhang
Favorite
Zhang, Ludan
1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Ludan Zhang
Favorite
Zhang, Meng

BeiGene USA, Inc.
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Meng Zhang
Favorite
Zhang, Ninghan
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Ninghan Zhang
Favorite
Zhang, Peiyi
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Peiyi Zhang
Favorite
Zhang, Qiang

Eli LIlly and Company
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Qiang Zhang
Favorite
Zhang, Wei

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Wei Zhang
Favorite
Zhang, Wenjie

Fujian Institute of Hematology, Fujian Medical University Union Hospital
1107 - Mechanisms of differential response to BTKi targeted therapy in patients with chronic lymphocytic leukemia
Wenjie Zhang
Favorite
Zhang, Xin

2. Department of Hematology, Shandong Provincial Hospital, Shandong University
1018 - Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Xin Zhang
Favorite
1029 - Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1
Xin Zhang
Favorite
1033 - Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Xin Zhang
Favorite
1035 - ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway
Xin Zhang
Favorite
Zhang, Ya

1. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
2. Department of Hematology, Shandong Provincial Hospital, Shandong University
1018 - Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Ya Zhang
Favorite
1029 - Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1
Ya Zhang
Favorite
1033 - Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Ya Zhang
Favorite
1035 - ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway
Ya Zhang
Favorite
Zhang, Yang

1. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
1018 - Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Yang Zhang
Favorite
1033 - Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Yang Zhang
Favorite
Zhang, Yunxia

Department of Hematology, Nanfang Hospital, Southern Medical University
1025 - Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro
Yunxia Zhang
Favorite
Zhao, Sishu
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Sishu Zhao
Favorite
Zheng, Guangrong

University of Florida
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Guangrong Zheng
Favorite
Zhou, Daohong

UTHealth Science Center at San Antonio
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Daohong Zhou
Favorite
Zhou, Hui
3009 - Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Hui Zhou
Favorite
Zhou, Ziyuan

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Ziyuan Zhou
Favorite
1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Ziyuan Zhou
Favorite
1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Ziyuan Zhou
Favorite
Zhu, Huayuan

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Huayuan Zhu
Favorite
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Huayuan Zhu
Favorite
1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Huayuan Zhu
Favorite
1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Huayuan Zhu
Favorite
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Huayuan Zhu
Favorite
1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Huayuan Zhu
Favorite
1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Huayuan Zhu
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Huayuan Zhu
Favorite
1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Huayuan Zhu
Favorite
Zhu, Liying
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Liying Zhu
Favorite
Zinzani, Pier Luigi

Institute of Hematology “Seràgnoli” University of Bologna
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Pier Luigi Zinzani
Favorite
Zivkovic, Neno

University Hospital Centre Zagreb
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Neno Zivkovic
Favorite
Zölzer, Rebekka

Department I for Internal Medicine, University Hospital Cologne
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Rebekka Zölzer
Favorite
Zou, Dehui

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Dehui Zou
Favorite
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Dehui Zou
Favorite
Zucchetto, Antonella

Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Antonella Zucchetto
Favorite
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Antonella Zucchetto
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Antonella Zucchetto
Favorite